Source comparison
Best PT-141 Dosage for Hypoactive Sexual Desire: Clinical Comparison
0.5mg subcutaneous Test dose. Receptor tolerance check Subtherapeutic; mild flushing or warmth possible Minimal. Transient warmth in 10–15% of users Use once 72 hours before first therapeutic dose to confirm tolerance; do not rely on this dose for sexual benef
This comparison does not assign a generated winner or score.
- 0.5mg subcutaneous
- Test dose. Receptor tolerance check
- Subtherapeutic; mild flushing or warmth possible
- Minimal. Transient warmth in 10–15% of users
- Use once 72 hours before first therapeutic dose to confirm tolerance; do not rely on this dose for sexual benefit
- 1.0mg subcutaneous
- Low therapeutic dose
- 30% of women report satisfactory increase in desire and reduction in distress at this dose
- Nausea in 12–18%; flushing in 25%; headache in 10%
- Start here for first therapeutic use if 0.5mg test dose was tolerated; remain at this dose if effective. No benefit to increasing
- 1.5mg subcutaneous
- Mid-range therapeutic dose
- 60% of women achieve clinical response; statistically significant vs placebo in smaller cohorts
- Nausea in 25–30%; flushing in 35%; injection site erythema in 15%
- Appropriate escalation step if 1.0mg produces no change in desire after two uses
- 1.75mg subcutaneous
- FDA-approved standard dose
- 75% of women achieve clinical response (defined as ≥1.2-point increase on FSFI desire domain)
- Nausea in 40%; flushing in 40%; headache in 12%; hyperpigmentation with chronic use
- The evidence-supported dose for HSDD. Use if lower doses ineffective; most common cause of discontinuation is nausea, not lack of efficacy
- 2.0mg subcutaneous
- Upper limit (off-label)
- Marginal increase in response vs 1.75mg; no receptor saturation benefit beyond standard dose
- Nausea in 55%; severe nausea requiring antiemetic in 10–15%; flushing in 50%
- Not recommended. Side effect burden exceeds any marginal therapeutic gain; receptor ceiling reached at 1.75mg